CIK 0000886744 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 237000 | 253000 | ||
| Net income (USD) | -75.6 M | |||
| Diluted EPS (USD/shares) | -0.13 | -0.37 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-01 | 4 | 4 | 2026-09-30 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-05 |
| 2026-08-05 | S-8 | S-8 | |
| 2026-08-05 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-01 | 4 | 4 | 2026-06-30 |
| 2026-05-27 | 8-K | 8-K items 5.02,5.07,9.01 | 2026-05-20 |
| 2026-05-26 | 4 | 4 | 2026-05-20 |
| 2026-05-26 | 4 | 4 | 2026-05-20 |
| 2026-05-26 | 4 | 4 | 2026-05-20 |
| 2026-05-26 | 4 | 4 | 2026-05-20 |
| 2026-05-26 | 4 | 4 | 2026-05-20 |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-08 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-06 | 10-Q | 10-Q | 2026-03-31 |
| 2026-04-14 | 4 | 4 | 2026-04-13 |
| 2026-04-14 | 3 | 3 | 2026-04-13 |
| 2026-04-07 | ARS | ARS | 2025-12-31 |
| 2026-04-07 | DEFA14A | DEFA14A | |
| 2026-04-07 | DEF 14A | DEF 14A | 2026-05-20 |
| 2026-04-01 | 4 | 4 | 2026-03-31 |
| 2026-03-26 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-03-26 | 4 | 4 | 2026-03-25 |
| 2026-03-26 | 3 | 3 | 2026-03-25 |
Forms on file (last 1,000): 4 441, 8-K 225, 10-Q 50, SC 13G/A 36, 3 30, DEFA14A 19, 424B5 18, DEF 14A 17. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=GERN (0.002 USD), /gw/filings/filings?ticker=GERN&form=8-K, /gw/filings/facts?ticker=GERN&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange